You are currently viewing Assay Ready Cells! Always Ready to Perform the Assay

Assay Ready Cells! Always Ready to Perform the Assay

Assay ready cells are cryopreserved highly functional cells and can be used in cell-based assays, ready to be used for many downstream applications. Basically, like any other reagent, the cells are applied to the assay instantly after thawing. Introduced initially in the drug discovery process where assay ready frozen Instant Cells help to streamline cell-based high-throughput screening campaigns, the methodology now has been accepted for a much broader scope of applications and industries. The preparation of assay ready Frozen Instant Cells is not so much a piece of magic but a combination of good cell culture practice, careful handling, and individually optimized cryopreservation protocols.

Cryopreservation techniques uncouple cell culturing from drug-screening activities and allow the use of cells as reagents, just like enzymes in biochemical assays.

ADVANTAGES OF USING ASSAY READY CELLS

  • Assay Ready Cells are time-saving, cost-effective, high quality, functionally active and authentically characterized cells for assay development and screening.
  • Assay Ready Cells facilitate high-throughput screening of new drug candidates through various bioassays.
  • Assay Ready Cells are considerably less labor intensive and allows more flexibility in laboratory testing.
  • It is always better to The ability to use the same, optimized population of cells for better consistency and reproducibility of your assay output. Control of the cellular component, which is the most variable aspect of most statements. cell-based potency assays, allowed detection of more minor contributors to variability.
  • The use of cryopreserved cells instead of cells that are continuously maintained in culture decreases day-to-day variation, removes passage effects and improves the consistency of cell-based assay results. The cryopreserved cells will allow you to maintain passage number, without compromising genotypic and phenotypic markers.
  • Use of assay ready cells can dramatically lower batch-to-batch variability as the cells are more uniform and the time from thawing to assay is much shorter.
  • Assay ready cells are immediately available, perform reliably, and can provide better quality of bioassays in cell-based screening

DEVELOPMENT OF ASSAY READY FROZEN CELLS

Considering the criticality of the cell-based assays, it is very important to get reproducible cells with similar genotypic and phenotypic characters. Assay ready cells can be used like a reagent without prior cultivation or passaging, and can be prepared in large homogenous batches and get pre-validated to minimize cell culture-dependent variances.

Production Process of assay ready frozen instant cell
Figure 1: Production Process of assay ready frozen instant cell

 

DIFFERENCE BETWEEN USING TRADITIONAL CELL CULTURE METHOD AND ASSAY READY CELLS

Traditional Cell Culture Workflow
Figure 2: Traditional Cell Culture Workflow

 

The Assay Ready Cell Workflow
Figure 3: The Assay Ready Cell Workflow

TYPE OF INVITRO MODELS THAT CAN BE DEVELOPED BY ASSAY READY CELLS

Organoids: Organoids are three-dimensional (3D) multi-cellular, microtissues derived from stem cells that closely mimic the complex structure and functionality of human organs.  They offer more accurate and physiologically relevant representation of complex in vivo cell responses and interactions compared to traditional 2D cell cultures

Hybrid models: There is no cell type containing all of the factors that make them suitable to study different targeted diseases. Thus, the possibility of using the cell biological approach of fusing two different cells to combine desirable functions is being investigated. Hybrid models are being generated by fusing primary cell lines expressing functions; which might have been absent with permanent, non-tumorigenic cell lines.

3D invasion models: Assay ready cells can be used to study cancer models by developing 3D cell invasion in three dimensions.

Bioprinting: Assay ready cells can be used to develop 3D bioprinting. It is a technique that uses living cells, biomaterials (Bioinks), and other components to create tissue and organs, which can be in different research areas, such as tissue engineering and new drug development.

Invitro small intestine model: This model can be developed by human-derived cultured and preserved cells.it is 3D structure with villi like and crypt structure.

APPLICATIONS OF ASSAY READY CELLS

They can be applied to the assay immediately after thawing. Some types of cell-based assays include:

Cell proliferation assays

Quantify the number of healthy cells in a population and/or the rate of growth of a population of cells. Cell proliferation assays are generally used for drug screening to detect whether the test molecules have effects on cell proliferation or display direct cytotoxic effects.

Cell viability assays

Quantify the number of healthy cells in a population. Cell viability assays are used to determine proportion of live, healthy cells within a population, to optimize culture or experimental conditions, and to measure cell survival following treatment with compounds, such as during a drug screen.

Cell migration and invasion assays

Evaluate how cells move in response to external signals. Migration is a key property of live cells and critical for normal development, immune response, and disease processes such as inflammation and cancer metastasis. Methods to examine cell migration are very useful and important for a wide range of biomedical research such as cancer biology, immunology, vascular biology, cell biology and developmental biology

Reactive oxygen species assays

(ROS) detection assays allow for the identification of changes in the oxidative status of cells in culture. Generation of reactive oxygen species (ROS) is also a marker for aerobic organisms. in healthy cells, occurs at a controlled rate. Generation of ROS is associated with variety of pathological events such as aging, neurodegenerative disorders, atherosclerosis, carcinogenesis, and ischemia reperfusion injury,

Cytotoxicity assays

The cytotoxicity assay is one of the biological evaluation and screening tests. They use cells in vitro to observe the cell growth, reproduction and morphological effects by medical devices and test substances.

Reporter gene assays

Genetically engineered cells with reporter gene are used for the detection of drug potency and other biological process.

Cell surface receptor binding assays

The cell-based binding assay is one of the important experiment models, which provides convenience for early antibody screening and validation process. The complement receptor ligand binding assay is a laboratory test used to assess the interaction between complement receptors and their ligands.

ASSAY-READY CELLS AND ETHICAL ADVANTAGES

As per the criteria set forth by the International Council for Harmonization (ICH), in vitro techniques should be given preference in safety testing wherever feasible, particularly during the first phases of drug development. Assay-ready cells align with current regulatory and ethical norms by providing scientifically verified, compassionate alternatives to animal-based testing. This makes them a better option for drug industries exploring to comply with ethical norms and minimize the usage of animals.

In the past, researchers studying drug metabolism, toxicity, and disease models had to rely on human tissue samples or animal models. However, the utilization of human tissues may raise ethical concerns about permission, tissue donation, and potential exploitation. While in order to investigate human physiology without invasive procedures or the exploitation of human donors, they can be produced from pre-existing cell lines or ethically obtained stem cells. The isolation of primary cells from either human or animal tissues preserves the properties of the original tissue. They are therefore more predictive of the behavior of cells in-vivo, which is particularly significant in ADME studies.

CONCLUSION

As a leading cell culture research organization in India, Kosheeka provide Assay Ready Cells tailored for diverse applications, including high-throughput screenings, drug safety, and toxicity profiling. Our ready-to-use cells, such as embryonic stem cells, pluripotent stem cells, hepatocytes, cardiomyocytes, keratinocytes are optimized for immediate uses. They ensuring consistency and reproducibility in toxicity studies and other assays. With Immediate availability of Kosheeka’s Assay Ready Cells for experiments researchers can achieve efficient workflows. They can driving innovation in drug development and safety evaluation. Kosheeka’s Assay Ready Cells eliminate the need for continuous culture.

FREQUENTLY ASKED QUESTIONS

Q: What are Assay Ready Cells?

They are cryopreserved highly functional cells and can be used in cell-based assay without prior cultivation or cell passaging.

Q: What are different in vitro models that can be developed by Assay Ready Cells?

  • Organoids
  • Hybrid models
  • 3D invasion models
  • Bioprinting
  • Biofilms
  • Invitro small intestine model.

Q: What are applications of assay ready cells?

They can be applied to the assay immediately after thawing. Some types of cell-based assays include:

  • Cell proliferation assays
  • Cell viability assays
  • Cell migration and invasion assays
  • Reactive oxygen species assays
  • Cytotoxicity assays
  • Reporter gene assays
  • Cell surface receptor binding assays

Dr.Swati Chitrangi (PhD)

Dr. Swati Chitrangi, PhD, Head of Production at Advancells Group, will be leading the session. With over 15 years of experience in regenerative medicine, stem cell therapy, and organoid research, Dr. Swati has contributed significantly to the advancement of disease modelling and drug discovery using organoids. Her deep expertise in precision medicine and patient-specific organoid development will provide valuable insights into the transformative potential of these advanced models.
Dr. Swati holds a PhD in Bioengineering and an MBA in Strategic Management from the Indian Institute of Management (IIML-2025), providing her with a unique blend of scientific and business acumen. She has been involved in several pioneering research projects and has authored publications on patient-derived organoids for precision oncology, the derivation of human iPSC lines, and engineered 3D in vitro models for drug toxicity studies. Her work emphasizes the translation of cutting-edge stem cell technology into practical applications for patient care and drug development.

Leave a Reply